Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Proforma Information (Details)

v3.24.3
Business combinations - Proforma Information (Details) - USD ($)
$ in Thousands
3 Months Ended 5 Months Ended 9 Months Ended
Jun. 01, 2023
Sep. 30, 2024
Sep. 30, 2023
May 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Business Acquisition [Line Items]            
Gain on bargain purchase           $ 22,049
Share-based compensation expense   $ 3,054 $ 3,183   $ 9,215 8,696
TCR2 Therapeutics            
Business Acquisition [Line Items]            
Revenue           60,050
Net loss           (129,684)
Acquisition-related costs incurred by TCR2           9,000
Gain on bargain purchase $ 22,049         22,000
Acquisition-related costs           $ 7,346
Share-based compensation expense       $ 1,000